 |
97 Diseases |  |
247 Trials |
|
247 Trials |  |
14602 News |  |
| «12...3233343536373839404142...170171» |
- Savaysa (edoxaban) / Daiichi Sankyo
Safety of direct oral anticoagulants as compared to low molecular weight heparin in treating venous thromboembolism in patients with primary brain tumors and brain metastases (West/Central Hall) - Sep 28, 2022 - Abstract #SNO2022SNO_780;
Introduction: Patients with brain tumors (PBTs) have a 20 to 30% incidence of venous thromboembolism (VTE) Recently, new direct oral anticoagulants (DOACs) such as rivaroxaban, apixaban, dabigatran and edoxaban, have gained popularity in treating VTE in cancer patients due to ease of administration and favorable safety profile. In the small number of prospective and retrospective studies which have evaluated the safety of DOAC in comparison to LMWH in brain tumors, the use of DOAC appears to be safe with no increase in the risk of ICH over LMWH.
- | Tybost (cobicistat) / Gilead, Prezcobix (darunavir/cobicistat) / Gilead, J&J
Enrollment change: CLOTRx: Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers (clinicaltrials.gov) - Sep 27, 2022
P1, N=40, Recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
In the small number of prospective and retrospective studies which have evaluated the safety of DOAC in comparison to LMWH in brain tumors, the use of DOAC appears to be safe with no increase in the risk of ICH over LMWH. N=24 --> 40
- | rivaroxaban / Generic mfg., aspirin / Generic mfg.
Enrollment closed, Enrollment change: Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk (clinicaltrials.gov) - Sep 27, 2022
P=N/A, N=650, Active, not recruiting, Sponsor: Maatschap Cardiologie Zwolle
N=24 --> 40 Recruiting --> Active, not recruiting | N=1000 --> 650
- | rivaroxaban / Generic mfg.
Journal: Is rivaroxaban an all-rounder? (Pubmed Central) - Sep 25, 2022
Recruiting --> Active, not recruiting | N=1000 --> 650 No abstract available
- | Journal: Association of Oral Anticoagulation Prescription with Clinical Events in Patients with an Asymptomatic Unrepaired Abdominal Aortic Aneurysm. (Pubmed Central) - Sep 24, 2022
These findings suggest that AAA-related events but not MACE may be reduced in patients prescribed an anticoagulant medication. Due to the inherent biases of observational studies, a randomized controlled trial is needed to assess whether anticoagulation reduces the risk of AAA-related events.
- | rivaroxaban / Generic mfg.
Journal: Association between Genetic Polymorphisms and Bleeding in Patients on Direct Oral Anticoagulants. (Pubmed Central) - Sep 24, 2022
Rivaroxaban and anemia showed significant association with bleeding in both models...The predicted bleeding risks of bleeding in patients with 0, 1, 2, 3, 4, 5, 6, 7 and 8 points from the logistic regression curve were 0.8%, 2.0%, 5.4%, 5.2%, 12.5%, 26.9%, 47.0%, 64.3% and 82.3%, respectively. The study results can be used for enhancing individualized treatment strategies in patients taking DOACs, helping clinicians predict the bleeding risk.
- | rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., warfarin / Generic mfg.
Journal: Anticoagulation in atrial fibrillation associated with mitral stenosis. (Pubmed Central) - Sep 24, 2022
The safety and efficacy of using rivaroxaban, a direct factor Xa inhibitor anticoagulant, were demonstrated in the RIVER trial with a sample of 1005 patients with AF and bioprosthetic mitral valve...A randomized, open-label study (DAVID-MS) is underway to compare the effectiveness and safety of dabigatran and warfarin therapy for stroke prevention in patients with AF and moderate or severe mitral stenosis. No abstract available
- | Savaysa (edoxaban) / Daiichi Sankyo
Journal: Obesity paradox in atrial fibrillation and its relation with the new oral anticoagulants. (Pubmed Central) - Sep 24, 2022
Despite the fact that the mechanisms that lead to this paradox are still uncertain, adequate anticoagulation in obese patients seems to play an important role in reducing adverse events in this group. In this perspective article, the authors discuss the relationship between new oral anticoagulants (NOACs), namely, apixaban, edoxaban and rivaroxaban (factor Xa inhibitors) and dabigatran (direct inhibitor of thrombin), and the obesity paradox, seeking to deepen the understanding of the mechanism that leads to this paradox.
- || warfarin / Generic mfg., apixaban / Generic mfg.
Retrospective data, Review, Journal: Comparison of the Efficacy and Safety of Apixaban and Warfarin in the Prevention of Stroke in Patients With Non-valvular Atrial Fibrillation: A Meta-Analysis. (Pubmed Central) - Sep 23, 2022
The current meta-analysis concluded that apixaban, compared to warfarin in patients with non-valvular atrial fibrillation showed a reduction in stroke and systemic embolism. Apixaban has also a better safety profile in terms of reduction in overall major bleeding events.
- | rivaroxaban / Generic mfg.
Journal: Clinical features and posttreatment monitoring of dogs administered rivaroxaban (2018-2020): 19 cases. (Pubmed Central) - Sep 23, 2022
aXa was most commonly measured in dogs receiving rivaroxaban with confirmed or suspected thrombosis. Dogs in this study received a range of rivaroxaban dosages and attained variable aXa values that were not directly correlated with dosage.
- | Sulonex (sulodexide) / Alfasigma
Journal: ISTH guidelines for antithrombotic treatment in COVID-19. (Pubmed Central) - Sep 23, 2022
Recommendations in this guideline are based on high-/moderate-quality evidence available through March 2022. Focused updates will incorporate future evidence supporting changes to these recommendations.
- | rivaroxaban / Generic mfg.
In meiner Umgebung nehmen bei dieser Indikation alle Xarelto, hat das beste Standing bei den behandelnden Ärzten (Twitter) - Sep 22, 2022
- || rivaroxaban / Generic mfg., aspirin / Generic mfg.
Review, Journal: Comparison of Aspirin and Rivaroxaban Plus Aspirin in the Management of Stable Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomized Controlled Trials. (Pubmed Central) - Sep 21, 2022
However, the combination treatment is associated with increased of major bleeding. Therefore, the combination of rivaroxaban and aspirin is superior to monotherapy in the management of patients with a high risk of developing MACEs and MALEs.
- ||| rivaroxaban / Generic mfg., aspirin / Generic mfg.
New trial, Combination therapy: Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants (clinicaltrials.gov) - Sep 21, 2022
P=N/A, N=60, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- ||| rivaroxaban / Generic mfg.
Trial completion, Enrollment change: A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK) (clinicaltrials.gov) - Sep 21, 2022
P=N/A, N=2601, Completed, Sponsor: Bayer
Therefore, the combination of rivaroxaban and aspirin is superior to monotherapy in the management of patients with a high risk of developing MACEs and MALEs. Active, not recruiting --> Completed | N=5000 --> 2601
- || Clinical, Journal: Recurrent Thrombi in an Obese Patient With History of Bariatric Surgery Despite Anti-Xa Therapy. (Pubmed Central) - Sep 21, 2022
In this case and similar instances, there could be a need for anticoagulant dose adjustments, different INR goals, or a combination of different anticoagulants. Providers should take an individualized approach to patients who have had bariatric surgery with elevated BMI as a key factor in anticoagulant selection.
- || Multaq (dronedarone) / Sanofi
PK/PD data, Journal: Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration. (Pubmed Central) - Sep 21, 2022
Dronedarone co-administration increased the exposure of rivaroxaban and apixaban and might potentiate major bleeding risks. Reduced apixaban and rivaroxaban dosing regimens are recommended when dronedarone is co-administered to patients with AF.
- | Journal: The safety of continuous fascia iliaca block in patients with hip fracture taking pre-injury anticoagulant and/or antiplatelet medications. (Pubmed Central) - Sep 21, 2022
In this retrospective review, we did not identify any complications that were directly associated with the FICB procedure. Fascia iliaca block with continuous infusion catheter placement can be safely performed on patients who are on therapeutic anticoagulant and/or antiplatelet agents.
- | Savaysa (edoxaban) / Daiichi Sankyo
Journal: Evaluation of newly-developed modified diluted prothrombin time reagent in non-valvular atrial fibrillation patients with direct oral anticoagulants: A comparative study with conventional reagents. (Pubmed Central) - Sep 21, 2022
Compared with other PT and dPT reagents, mdPT reagent showed sharper slope to all direct FXa inhibitors, and higher correlation to apixaban and comparable correlation to edoxaban and rivaroxaban. This new reagent is expected to be a coagulation screening assay having a consistently high response to any types of direct FXa inhibitors.
- | rivaroxaban / Generic mfg.
Retrospective data, Journal, Real-world evidence: A retrospective study of real-world effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation and venous thromboembolism in Saudi Arabia. (Pubmed Central) - Sep 20, 2022
However, for individuals with VTE and NVAF, the 20 mg dose looked to be more efficacious than the pivotal trial outcomes. Furthermore, among patients with VTE and NVAF, rivaroxaban was linked to a decreased incidence of safety events such as recurrent thrombosis, recurrent stroke, MI, major bleeding, and non-major haemorrhage in a real-world environment.
- || rivaroxaban / Generic mfg.
Retrospective data, Review, Journal: Latest outcomes of transcatheter left atrial appendage closure devices and direct oral anticoagulant therapy in patients with atrial fibrillation over the past 5 years: a systematic review and meta-analysis. (Pubmed Central) - Sep 20, 2022
Based on a literature search using PubMed, EMBASE, Cochrane Library, and Web of Science databases between January 2015 and December 2020, eight LAAC device studies that used WATCHMAN and Amulet, and three DOAC studies that used rivaroxaban, with a total of 24,055 AF patients (LAAC devices, n = 2855; DOAC, n = 21,200), were included...However, further follow-up is needed. Concomitant anticoagulant and antiplatelet therapies should be further evaluated to find the optimal regimen for AF patients with LAAC devices.
- | Journal, HEOR: Thromboprophylaxis of Patients Submitted to Total Hip and Knee Arthroplasty: A Cost-Effectiveness Assessment From the Perspective of the Brazilian National Health System. (Pubmed Central) - Sep 20, 2022
Concomitant anticoagulant and antiplatelet therapies should be further evaluated to find the optimal regimen for AF patients with LAAC devices. Our model suggests that, in the Brazilian National Health System, apixaban is the most cost-effective alternative in preventing VTE after THA and TKA.
- | rivaroxaban / Generic mfg.
Journal: Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation. (Pubmed Central) - Sep 20, 2022
P3
Among patients with rheumatic heart disease-associated atrial fibrillation, vitamin K antagonist therapy led to a lower rate of a composite of cardiovascular events or death than rivaroxaban therapy, without a higher rate of bleeding. (Funded by Bayer; INVICTUS ClinicalTrials.gov number, NCT02832544.).
- || Trial completion date, Trial primary completion date, HEOR, Real-world evidence, Real-world: REATTAIN: Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) (clinicaltrials.gov) - Sep 19, 2022
P=N/A, N=70000, Active, not recruiting, Sponsor: Bayer
(Funded by Bayer; INVICTUS ClinicalTrials.gov number, NCT02832544.). Trial completion date: Aug 2022 --> Nov 2022 | Trial primary completion date: Aug 2022 --> Nov 2022
- | rivaroxaban / Generic mfg., aspirin / Generic mfg., clopidogrel / Generic mfg.
New P4 trial: COMPETE: Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale (clinicaltrials.gov) - Sep 19, 2022
P4, N=1000, Not yet recruiting, Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
- | rivaroxaban / Generic mfg.
Journal: Spontaneous Spinal Epidural Hematoma in a Patient on Rivaroxaban: A Case Report. (Pubmed Central) - Sep 18, 2022
Trial completion date: Aug 2022 --> Nov 2022 | Trial primary completion date: Aug 2022 --> Nov 2022 No abstract available
- | rivaroxaban / Generic mfg.
Journal: Rivaroxaban, a New Molecule with Potential to Balance Bleeding Risk and Ischemic Events in Patients with Chronic Coronary Syndrome. (Pubmed Central) - Sep 18, 2022
Clinical trial data on this new drug was certainly very encouraging, with evidence from the COMPASS trial and prespecified subgroups of COMPASS trials suggesting that the addition of rivaroxaban to aspirin was associated with a significantly lower risk of ischemic events, mortality, and tolerable bleeding profile in patients with CCS and high-risk factors. This combination is cost-effective and generally well tolerated in patients with CAD and/or PAD, as well as patients with CCS and multimorbidity or high-risk populations.
- | rivaroxaban / Generic mfg., enoxaparin sodium / Generic mfg.
Journal: Is Rivaroxaban Superior to Enoxaparin for Thromboprophylaxis in Hospitalized Patients of COVID-19?`. (Pubmed Central) - Sep 18, 2022
This combination is cost-effective and generally well tolerated in patients with CAD and/or PAD, as well as patients with CCS and multimorbidity or high-risk populations. No abstract available
- rivaroxaban / Generic mfg.
Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Covid-19: Primary Results of the PREVENT-HD Randomized Clinical Trial (Main Event I) - Sep 18, 2022 - Abstract #AHA2022AHA_6989;
P3
Rivaroxaban, administered for 35 days following the diagnosis of symptomatic COVID-19 in patients not requiring hospitalization and with at least 1 risk factor for thrombosis, did not reduce a composite endpoint of venous and arterial thrombotic events, hospitalization, and death. However, rivaroxaban was associated with a reduction in a secondary combined endpoint of symptomatic VTE and any arterial thrombotic event.
- rivaroxaban / Generic mfg.
Reduction in Acute Limb Ischemia with Rivaroxaban versus Placebo in Peripheral Artery Disease after Lower Extremity Revascularization (VOYAGER PAD) (N229) - Sep 18, 2022 - Abstract #AHA2022AHA_6952;
- rivaroxaban / Generic mfg.
Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With COVID-19: Primary Results of the PREVENT-HD Randomized Clinical Trial (Moderated Posters 5, Science and Technology Hall, Level 3) - Sep 18, 2022 - Abstract #AHA2022AHA_6929;
However, rivaroxaban was associated with a reduction in a secondary combined endpoint of symptomatic VTE and any arterial thrombotic event. Abstract is embargoed at this time.
- rivaroxaban / Generic mfg.
Real world use of vascular dose Rivaroxaban: Cost and Uptake (S106B) - Sep 18, 2022 - Abstract #AHA2022AHA_6843;
- | rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., warfarin / Generic mfg.
Journal: Hospitalized patients with isolated distal deep vein thrombosis: anticoagulation therapy or not? (Pubmed Central) - Sep 15, 2022
In hospitalized IDDVT patients, the thrombosis extension rate to PDVT/PE was low. Anticoagulation did not reduce the incidence of thrombosis extension of IDDVT and was not associated with all-cause mortality.
- | rivaroxaban / Generic mfg.
New trial, Preclinical: Rivaroxaban - Percutaneous Coronary Intervention (clinicaltrials.gov) - Sep 15, 2022
P=N/A, N=30, Completed, Sponsor: Bursa Postgraduate Hospital
- | rivaroxaban / Generic mfg.
Journal: Intentional overdose of rivaroxaban and alcohol: A case report. (Pubmed Central) - Sep 14, 2022
Anticoagulation did not reduce the incidence of thrombosis extension of IDDVT and was not associated with all-cause mortality. No abstract available
- | Preclinical, Journal: Tyrosine kinase inhibitors and direct oral anticoagulants: In vitro evaluation of drug-drug interaction mediated by P-Glycoprotein. (Pubmed Central) - Sep 14, 2022
A risk of drug-drug interaction was found in vitro between TKIs and DOACs. In vivo pharmacokinetic studies are needed to ensure the safety of prescribing DOACs in cancer patients on TKI therapy, in order to avoid major, potentially preventable bleeding events.
- || Paxlovid (nirmatrelvir and ritonavir) / Pfizer
PK/PD data, Journal: Physiologically Based Pharmacokinetic Modelling-Guided Dose Management of Oral Anticoagulants when Initiating Paxlovid for COVID-19 Treatment. (Pubmed Central) - Sep 14, 2022
As INR only recovered 2 weeks post-Paxlovid treatment, a longer surveillance INR for warfarin becomes important. Our PBPK-guided simulations evaluated clinically important yet untested DDIs and supports clinical studies to ensure proper anticoagulation management of COVID-19 patients with chronic coagulative abnormalities when initiating Paxlovid therapy.
- | rivaroxaban / Generic mfg., apixaban / Generic mfg.
Journal: Safety and efficacy of Apixaban and Rivaroxaban in obese patients with acute thrombosis/embolism. (Pubmed Central) - Sep 14, 2022
Our PBPK-guided simulations evaluated clinically important yet untested DDIs and supports clinical studies to ensure proper anticoagulation management of COVID-19 patients with chronic coagulative abnormalities when initiating Paxlovid therapy. Our study indicates that apixaban and rivaroxaban are not associated with an increase in VTE recurrence in the morbidly obese; however, bleeding rates were slightly higher in the rivaroxaban group compared to the apixaban group.
- | rivaroxaban / Generic mfg., apixaban / Generic mfg.
Retrospective data, Journal: Safety and effectiveness of direct oral anticoagulants in patients with nephrotic syndrome: a report of 21 cases. (Pubmed Central) - Sep 14, 2022
Our study indicates that apixaban and rivaroxaban are not associated with an increase in VTE recurrence in the morbidly obese; however, bleeding rates were slightly higher in the rivaroxaban group compared to the apixaban group. In this case series, no new TE and only minor bleeding complications were observed among adult NS patients treated with DOAC.
- | rivaroxaban / Generic mfg.
Retrospective data, Journal: Outcome of anticoagulation with rivaroxaban in patients with non-retrieved inferior vena cava filters for the prevention of filter thrombosis: a retrospective cohort study. (Pubmed Central) - Sep 14, 2022
It is necessary to perform a concomitant anticoagulation in patients with non-retrieved filters. Rivaroxaban can be an alternative anticoagulant option for the prevention of filter thrombosis.
- | Savaysa (edoxaban) / Daiichi Sankyo, Praxbind (idarucizumab) / Boehringer Ingelheim
Journal: Protocolized management of bleeding in hospitals in The Netherlands in patients treated with direct oral anticoagulants. (Pubmed Central) - Sep 14, 2022
From August to December 2020 a nationwide survey among all 70 hospitals in the Netherlands was conducted on their protocols for management of bleeding in patients treated with DOACs (i.e. apixaban, edoxaban, rivaroxaban and dabigatran)...While the first choice treatment for severe bleeding under dabigatran was idarucizumab in 96% of protocols, considerably more therapeutic options (mostly different Prothrombin Complex Concentrate (PCC) doses) are described for Xa inhibitors...Protocols vary in the content of information provided and often do not include information, especially for diagnostic criteria and criteria for establishing the effectiveness of the intervention. The results of this study can assist in improving and harmonizing the protocols.
- || metformin / Generic mfg., apixaban / Generic mfg.
PK/PD data, Preclinical, Journal: LC-MS/MS Method Assay for Simultaneous Determination of the Apixaban and Metformin in Rat Plasma: Assessment of Pharmacokinetic Drug-Drug Interaction Study. (Pubmed Central) - Sep 14, 2022
The comparison of pharmacokinetic parameters of MET in the single and co-administrated groups showed significant difference in t1/2 from 2.83 ± 1.81 to 3.97 ± 0.57 h and Cmax from 4015.76 ± 873.23 to 3153.6 ± 1012.51 ng/mL. The results indicated that drug-drug interactions (DDI) occurred might be owing to APB affect one or all of OCTs, MATE1, MATE2-K.
- rivaroxaban / Generic mfg., aspirin / Generic mfg.
ASPIRIN AND RIVAROXABAN IN VASCULAR DOSE ARE THE NEW GOLD STANDARD REGIMEN FOR PATIENTS WITH LEAD (Plenary 1) - Sep 12, 2022 - Abstract #ESVS2022ESVS_500;
- rivaroxaban / Generic mfg., aspirin / Generic mfg.
ESVS ANTITHROMBOTIC GUIDELINE CHALLENGES: ASPIRIN AND RIVAROXABAN FOR LEAD (Plenary 1) - Sep 12, 2022 - Abstract #ESVS2022ESVS_430;
- | AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Journal, Real-world evidence: Real-World Reversal of Factor Xa Inhibition in the Setting of Major Life-Threatening Bleeding or Urgent Surgery. (Pubmed Central) - Sep 12, 2022
Guideline use resulted in similar rates of effective hemostasis with a higher incidence of VTE in patients receiving AA. Further exploration with a larger, prospective study to evaluate these findings is warranted.
- | Savaysa (edoxaban) / Daiichi Sankyo, Bevyxxa (betrixaban) / AstraZeneca
Journal: Risk of bleeding among individuals on direct acting oral anticoagulants: an academic medical center cohort study. (Pubmed Central) - Sep 12, 2022
Significant risk factors of GI bleeding included: clopidogrel (OR 1.71, 95% CI 1.16-2.52); and previous GI bleeding episodes (OR 7.73, 95% CI 5.36-11.16). Exposure to corticosteroids (OR 1.50, 95% CI 1.20-1.87) and previous GI bleeding (OR 1.61 95% CI 1.10-2.35) were associated with an increase in bleeding at other anatomical sites (not GI included).
- || rivaroxaban / Generic mfg.
Clinical data, Journal, Real-world evidence: Real-world rivaroxaban use in fragile Asian patients with atrial fibrillation: The impact of plasma concentration on clinical outcomes. (Pubmed Central) - Sep 12, 2022
Exposure to corticosteroids (OR 1.50, 95% CI 1.20-1.87) and previous GI bleeding (OR 1.61 95% CI 1.10-2.35) were associated with an increase in bleeding at other anatomical sites (not GI included). No abstract available
- | rivaroxaban / Generic mfg.
Journal: Arm swelling and dyspnea under ongoing treatment with rivaroxaban (Pubmed Central) - Sep 12, 2022
No abstract available No abstract available
- || rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg.
Review: Direct oral anticoagulants versus standard anticoagulation in children treated for acute venous thromboembolism. (Pubmed Central) - Sep 11, 2022
For pediatric VTE, previous meta-analyses have emphasized the epidemiology, risk factors, and the use of traditional anticoagulants, and seldom reported the use of novel oral anticoagulants. This is the first meta-analysis of randomized controlled trials that focuses on the efficacy outcomes and safety endpoints of DOACs compared with standard anticoagulation in pediatric VTE.
- | rivaroxaban / Generic mfg.
Journal: Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp. (Pubmed Central) - Sep 11, 2022
Imatinib increased the bleeding risks of rivaroxaban, while sunitinib had a risk of reducing therapy efficiency. Therefore, more attention should be paid to aviod harmful DDIs in the combinations of rivaroxaban with TKIs.